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1. Introduction 
Consumption of soy foods has been associated, at least in part, with lower incidences of a 
number of chronic diseases indicated by epidemiological studies (1-4). Soy-based foods 
have been consumed in Asian countries such as China, Japan and Korea for many 
centuries. The lower rates of several chronic diseases in Asia, including cardiovascular 
diseases and certain types of cancer, have been partly attributed to consumption of large 
quantities of soy foods (5, 6). 
Soy-based food was first introduced on a large scale to the general U.S. population as a 
source of high quality protein. A significant increase in soy food consumption during the 
last decade of the 20th century occurred because of the health benefits soy food might offer 
independent of their nutrient content (7). In the last few decades, extensive efforts have 
been made towards identifying bioactive components in soy foods that are responsible for 
the health benefits. Among them, isoflavones and soy proteins are the two major groups 
of components that have received the most attention (8-11). Isoflavones belong to a broad 
group of plant-derived compounds that have structural and functional similarities to 
estrogens, which has led to the term phytoestrogens (12, 13). Indeed, more than half of the 
soy-related papers are related to isoflavones (7). The analysis, bioavailability and the 
health effects of isoflavones have been extensively studied and frequently reviewed (12, 
14-21). Consumption of isoflavones has been suggested to have multiple beneficial effects 
in a number of chronic diseases and medical conditions (4, 22, 23). However, 
accumulating evidence has also suggested that isoflavones only reflected certain aspects 
of the health effects associated with soy consumption. Other components in soy, such as 
soyasaponins, phytic acid or plant sterols, display a wide range of bioactivities, including 
anti-cancer, anti-oxidative, anti-viral, cardiovascular protective effects, and hepato-
protective actions (24).  
                                                 
* Mention of trade names or commercial products in this publication is solely for the purpose of 
providing specific information and does not imply recommendation or endorsement by the U.S. 
Department of Agriculture.   
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In this chapter, we summarize the structural characterization of major phytochemicals in 
soybean and soy-based foods. Potential health benefits of these phytochemicals, especially 
the non-isoflavone phytochemicals and their preventive effects of chronic and lifestyle-
related diseases, are also briefly discussed.  
2. Phytochemicals in soybean and their health effects  
In this section, the structural characterizations of major phytochemicals that naturally exist 
in soybean are firstly summarized. Composition and contents of phytochemicals in soybean 
vary dramatically depending on the variety and growing environment. In general, the  
 
Fig. 1. The chemical structures of isoflavones in soy. 
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contents of major phytochemicals from high to low in soybean are: phytic acid (1.0-2.2%) 
(25), sterols (0.23-0.46%) (26), saponins (0.17-6.16%) (27), isoflavones (0.1-0.3%) (23), and 
lignans (0.02%) (28). Secondly, the potential health effects of the major phytochemicals are 
outlined. For many years, the studies of health effects of soybean phytochemicals primarily 
focused on isoflavones. However, other phytochemicals in soy, such as soyasaponins, 
phytosterols, lignans, phytic acid, and oligosaccharides, have also been found to exert 
biological activities. These may contribute to overall health effects observed with soy 
consumption.  
2.1 Isoflavones 
2.1.1 Chemical characteristics of isoflavones  
Isoflavones have been known to exist in plants for over 100 years. And soy, including the 
foods derived from this legume, is considered as a richest dietary source of isoflavones (7). 
Isoflavones (3-phenyl-4H-1-benzopyran-4-one) are a subclass of more ubiquitous flavonoids, 
while they differs from flavone (2-phenyl-4H-1-benzopyran-4-one) in that the phenyl group 
(B ring) is connected to position 3 instead of position 2 (Figure 1) (29). Soy mainly contains 
three isoflavones, namely daidzein (7,4'-dihydroxyisoflavone) (1), genistein (5,7,4'-
trihydroxyisoflavone) (2) and glycitein (6-methoxy-7,4'-dihydroxyisoflavone) (3). Genistein 
and daidzein have been found in relatively high concentrations in soybean and most soy-
based foods. In soybean and non-fermented soy foods, they are generally present as one of the 
following three β-glucoside conjugates: a) the corresponding glucosides: daidzin (daidzein 7-
O--D-glucoside) (4), genistin (genistein 7-O--D-glucoside) (5) and glycitin (glycitein 7-O--D-
glucoside) (6); b) the corresponding acetylglucosides: 6-O-acetyldaidzin (7), 6-O-
acetylgenistin (8) and 6-O-acetylglycitin (9); and c) the corresponding malonylglucosides: 6-O-
malonyldaidzin (10), 6-O-malonylgenistin (11) and 6-O-malonylglycitin (12) (29). In addition 
to β-glucoside conjugates, isoflavones conjugated with other sugar moieties, including 6-O--
D-arabinose-genistin (13) and 6-O--D-xylose-genistin (14). Other isoflavones, including    
2,6-O –diacetyloninin (15), and two dihydro-isoflavanones, dihydrodaidzin (16) and 
dihydrogenistin (17) were reported recently in the last ten years (30, 31).  
2.1.2 Health effects of isoflavones 
Health effects of isoflavones were initially thought to be related to their estrogenic activity (23). 
The molecular structures of isoflavones, especially genistein (2), are similar to that of 17ǃ-
estradiol (Figure 2). Isoflavones can bind to both ǂ and ǃ isoforms of esterogen receptor (ER), 
but their binding affinity to ERǃ is about 20 times higher than that to ERǂ (11). However, 
compared to physiological estrogen such as 17ǃ-estradiol, isoflavones have approximately 100 
times weaker affinities (32). Estrogen-like effects have been proposed as one of the major 
mechanism of action of isoflavone related to their health effects (8). A second mechanism of 
action of isoflavones, particularly of genistein, was discovered that genistein is a protein 
tyrosine kinase (PTK) inhibitor (8). Since then, isoflavones have been shown to affect a diverse 
array of intracellular signaling pathways (7). For instance, genistein and other isoflavones were 
found to interact with the peroxisome proliferator activated receptors, PPARǂ/Ǆ. These 
nuclear receptors are activated by fatty acids (PPARǂ) and prostaglandins (PPARǄ) and serve 
as transcription factors (32). As polyphenols, isoflavones also have antioxidant activities, 
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which were proposed as another important mechanism of action of isoflavones. However, 
isoflavones are not strong antioxidant may not be able to scavenge oxidants directly. They 
therefore are considered as antioxidants because of their effects on gene expression of enzymes 
that enhance antioxidant defenses (32). In addition to what has been discussed above, several 
other mechanism have been proposed for the activities of isoflavones, including 
stimulation/inhibition of enzyme activities involved in steroid synthesis and metabolism, 
targeting thyroid peroxidase, and inhibiting cancer metastasis (32). 
 
Fig. 2. The chemical structures of genistein and 17ǃ-estradiol.  
Consumption of isoflavones has been suggested to have multiple beneficial effects in a 
number of chronic diseases and medical conditions, including certain types of cancer (33-
35), heart disease (36-38), bone functions (39-42) and most recently, prevention of obesity 
(43, 44). Many excellent reviews regarding the different aspects of health effects of soy 
isoflavone can be found in the literatures, thus, only a brief outline of the health effects of 
isoflavones is provided in this chapter.  
2.1.2.1 Isoflavones and prevention of cancer 
The incidences of breast and prostate cancers are much higher in the United States and 
European countries compared to Asian countries such as Japan and China. One of the major 
differences in diet between these populations is that the Japanese and the Chinese consume a 
traditional diet high in soy products (35). Epidemiological evidence together with preclinical 
data from animal and in vitro studies strongly supported a correlation between soy isoflavone 
consumption and protection towards breast and prostate cancers (45-47). However, clinical 
studies assessing soy consumption and risk of breast cancer have yielded inconsistent results. 
In a most recent meta-analysis of prospective studies suggested that soy isoflavones intake is 
associated with a significantly reduced risk of breast cancer incidence in Asian populations, 
but not in Western populations. Further studies are warranted to confirm the finding of an 
inverse association of soy consumption with risk of breast cancer recurrence (48).  
Except for breast and prostate cancer, isoflavones also showed inhibitory effects on other 
hormone-related (e.g. endometrial, ovarian cancer) or hormone-independent cancers (e.g. 
leukemia and lung cancer) (49).  
2.1.2.2 Isoflavones and prevention of cardiovascular diseases 
A number of cardioprotective benefits have been attributed to dietary isoflavones including 
reduction in LDL cholesterol, inhibition of pro-inflammatory cytokines, cell adhesion 
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proteins and inducible nitric oxide production, potential reduction in the susceptibility of 
the LDL particle to oxidation, inhibition of platelet aggregation and an improvement in 
vascular reactivity (50).There are not randomized trials investigating the action of 
isoflavones on the incidence of clinical events. A few recent, well-designed studies have 
suggested an association of the ingestion of isoflavones with a reduction in the 
atherosclerotic burden, as indicated by the measurement of the intima-media thickness in 
carotid vessels (51).  
2.1.2.3 Isoflavones and bone health 
Observational studies have suggested that populations in Asia with a high dietary soy 
intake have a lower incidence of osteoporosis-related fractures when compared to Western 
populations. Isoflavones were suggested to prevent bone loss associated with menopause. 
Though extensive research using animal models has provided convincing data to indicate a 
significant improvement in bone mass or other end points following feeding with soyabean, 
results from intervention studies are still controversial (52). Additional research is needed to 
determine if isoflavones are an effective alternative to hormone replacement therapy for the 
prevention and treatment of osteoporosis (42). 
2.1.2.4 Isoflavones and prevention of obesity 
The prevalence of obesity and related diseases has increased rapidly in the Western world. 
Obesity is a disorder of energy balance and is associated with hyper-insulinemia, insulin 
resistance, and abnormalities in lipid metabolism, and it is one of the most important risk 
factors in the development of Type II diabetes, cardiovascular disease, atherosclerosis, and 
certain cancers (44). In recent years, evidence is emerging that soy isoflavones play a 
beneficial role in obesity and diabetes. Nutritional intervention studies in animals and 
humans indicate that consumption of soy isoflaovne or soy protein containing isoflavones 
reduces body weight and fat mass by lowering plasma cholesterol and triglycerides as well 
as by other mechanisms (43, 44, 53). Though the published results suggest a beneficial effect 
of soy isoflavone on obesity in human, these results also suggest that the effect may be 
dependent on whether the isoflavones are consumed in combination with soy protein (44).  
2.2 Soyasaponins and soyasapogenols  
2.2.1 Chemical characteristics of soyasaponins and soyasapogenols  
Saponins are sterol or triterpene glycosides that occur in a wide variety of plants. Soy-based 
foods are primary dietary sources of saponins (54). Chemical studies of saponins in soy 
track back to the 1930’s (55, 56). From the 1980’s to 1990’s, a number of papers, especially 
those published by Japanese researchers, significantly enriched our knowledge about 
chemical structure and diversity of this type of compounds in soy (57-65).  
Saponins in soy are often referred to soyasaponins. They differ from each other by the types 
of aglycones and the position where the sugar chain is attached. Generally, saponins are 
classified into four major groups, on the basis of their aglycone structures: group A, B, E and 
DDMP. Group A saponins have a hydroxyl group at the C-21 position, and group B 
saponins have a hydrogen atom at the same position. Group E saponins differ from group A 
and B by having a carbonyl group at C-22. Group B saponins may contain a DDMP (2,3-
dihydro-2,5-dihydroxy-6-methyl-4H-pyran-4-one) moiety at C-22 position, which are 
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denoted as DDMP saponins (66) (Figure 3) . DDMP soyasaponins and the acetylated 
soyasaponins of group A are sometimes considered as the genuine forms of groups A and B 
in soybeans. Group E soyasaponins are also considered to be phyto-oxidation products of 
group B soyasaponins (62, 67, 68). All four groups of soysaponins are glycosides of oleanan 
triterpene aglycones known as soyasapongenols. The oleanan aglycone contains one or 
more hydroxyl groups, and carboxylic groups and double bonds may also be present. The 
sugar moieties are generally attached at the C-3 position and sometimes at the C-22 postion 
of the aglycones. Group A soysaponins have two sugar chains, separately attached to C-3 
and C-22 positions of soyasapogenol A, except for A3 (33), which has only one sugar chain 
at C-3 (Table 1). C-3 sugar chain consists of two or three sugar residues, starting with a 
glucoronyl residue (glcUA) (67). C-22 side chain consists of two sugar residues, starting with 
an anarabinosyl, and ending with a xylosyl or glycosyl residue (58, 63, 65, 69) (Figure 3). 
Group B soysaponins have one sugar chain attached to the C-3 position of soyasapogenol B, 
with three exceptional compounds that have two sugar chains at C-3 and C-22 positions (41-
43) (57, 59, 69-71) (Figure 3). Most recently, a new soyasaponin Bh (40) was identified to bear 
an unique five-membered ring containing a hemiacetal functionality (Figure 3) (72). Group 
E soysaponins contain only one sugar chain at the C-3 position. They are considered to be 
formed by photo-oxidation at C-22 of group B (63, 69) (Figure 3). DDMP soyasaponins are 
categorized under B type soyasaponins by some researchers (27). Their structures were 
characterized as having DDMP group conjugated to group B at C-22 (67, 68, 73, 74) (Figure 
3). Similar to B type soyasaponins, DDMP soyasaponins only contain one sugar chain 
attached to C-3 postion. There are about 36 soysaponins identified in soybean. Their 
structures and the related references are listed (Tables 1-4).  
 
 
 
NO. name C-3 sugar chain C-22 sugar chain  molecular 
formula 
ref 
18 Aa (acetyl A4) glc(12)gal(12)glcUA(13) 2,3,4-tri-O-acetyl-xyl(13)ara(122) C64H100O31 65 
19 Ab (acetyl A1) glc(12)gal(12)glcUA(13) 2,3,4,6-tetra-O-acetyl-glc(13)ara(122) C67H104O33 64 
20 Ac  rha(12)gal(12)glcUA(13) 2,3,4,6-tetra-O-acetyl-glc(13)ara(122) C67H104O32 63 
21 Ad glc(12)ara(12)glcUA(13) 2,3,4,6-tetra-O-acetyl-glc(13)ara(122) C66H102O32 63 
22 Ae (acetyl A5) gal(12)glcUA(13) 2,3,4-tri-O-acetyl-xyl(13)ara(122) C58H90O26 65 
23 Af (acetyl A2) gal(12)glcUA(13) 2,3,4,6-tetra-O-acetyl-glc(13)ara(122) C61H94O28 64 
24 Ag (acetyl A6) ara(12)glcUA(13) 2,3,4-tri-O-acetyl-xyl(13)ara(122) C57H88O25 65 
25 Ah (acetyl A3) ara(12)glcUA(13) 2,3,4,6-tetra-O-acetyl-glc(13)ara(122) C60H92O27 64 
26 Ax glc(12)ara(12)glcUA(13) 2,3,4-tri-O-acetyl-xyl(13)ara(122) C63H98O30 69 
27 A1 glc(12)gal(12)glcUA(13) glc(13)ara(122) C59H96O29 64 
28 A2 gal(12)glcUA(13) glc(13)ara(122) C53H86O24 64 
29 A3 ara(12)glcUA(13) glc(13)ara(122) C52H84O23 64 
30 A4 glc(12)gal(12)glcUA(13) xyl(13)ara(122) C58H94O28 64 
31 A5 gal(12)glcUA(13) xyl(13)ara(122) C52H84O23 64 
32 A6 ara(12)glcUA(13) xyl(13)ara(122) C51H82O22 64 
33 A3 rha(12)gal(12)glcUA(13)  C48H78O19 58 
Table 1. The structures and molecular formulas of group A soyasaponins 
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NO. name C-3 sugar chain C-22 sugar 
chain 
molecular 
formula 
ref 
34 soyasaponin Ba or V glc(12)gal(12)glcUA(13)  C48H78O19 64 
35 soyasaponin Bb or I rha(12)gal(12)glcUA(13)  C48H78O18 59 
36 soyasaponin Bc or II rha(12)ara(12)glcUA(13)  C47H76O17 59 
37 soyasaponin Bbor III gal(12)glcUA(13)  C42H68O14 59 
38 soyasaponin Bc or Bx glc(12)ara(12)glcUA(13)  C47H76O18 69 
39 soyasaponin IV ara(12)glcUA(13)  C41H66O13 57 
40 soyasaponin Bh rha(12) gal(12)glcUA(13)  C48H78O19 72 
41 3-O--L-rhamnopyranosyl(12)-[-
D-glucopyranosyl-(13)--D-
galactopyranosyl(12)]--D-
glucuronopyranosyl-22-O-[-D-
glucopyranosyl(12)--L-
arabinopyranosyl]3,22,24-
trihydroxyolean- 12-ene 
rha(12)[glc(13)gal(12)] 
glcUA(13) 
glc(12)ar
a(122) 
C65H106O32 70 
42 3-O-[-L-rhamnopyranosyl(12)--
D-galactopyranosyl(12)]- -D-
glucuronopyranosyl-22-O-[-L-
rhamnopyranosyl(12)- -L-
arabinopyranosyl]3,22,24-
trihydroxyolean-12-ene 
rha(12)gal(12)glcUA(13) rha(12)ar
a(122) 
C59H96O26 71 
43 3-O-[-L-rhamnopyranosyl(12)--
D-galactopyranosyl(12)]- -D-
glucuronopyranosyl-22-O-[-L-
rhamnopyranosyl(12)- -D-
glucopyranosyl]3,22,24-
trihydroxyolean-12-ene 
rha(12)gal(12)glcUA(13) rha(12)gl
c(122) 
C60H98O27 71 
Table 2. The structures  and molecular formulas of group B soyasaponins 
NO. name C-3 sugar chain molecular 
formula 
ref 
44 soyasaponin Bd (sandosaponin A)  glc(12)gal(12)glcUA(13) C48H76O19 63 
45 soyasaponin Be (dehydrosoyasaponin I) rha(12)gal(12)glcUA(13) C48H76O18 63 
46 soyasaponin Bf glc(12)ara(12)glcUA(13) C47H74O18 69 
47 soyasaponin Bg rha(12)ara-(12)glcUA(13) C47H74O17 69 
Table 3. The structures and molecular formulas of group E soyasaponins 
NO. name C-3 sugar chain C-22 DDMP  molecular 
formula 
ref 
48 soyasaponin g glc(12)gal(12)glcUA(13) DDMP(222) C54H84O22 68 
49 soyasaponin a glc(12)ara(12)glcUA(13) DDMP(222) C53H82O21 74 
50 soyasaponin g or VI rha(12)gal(12)glcUA(13) DDMP(222) C54H84O21 68 
51 soyasaponin a rha(12)ara(12)glcUA(13) DDMP(222) C53H82O20 68 
52 soyasaponin g gal(12)glcUA(13) DDMP(222) C48H74O17 68 
53 soyasaponin a ara(12)glcUA(13) DDMP(222) C47H72O16 68 
Table 4. The structures and molecular formulas of group DDMP soyasaponins 
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Fig. 3. The chemical structures of groups A, B, Bh, E and DDMP soyasaponins in soy. 
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Soyasapogenols are aglycones of soyasaponins. They can be obtained by acid or alkaline 
hydrolysis of soyasaponins. Though soyasapogenols don’t exist in soy bean naturally, they 
may exist in certain soy products through food processing. Five soyasapogenols A (54), B 
(55), C (56), D (57) and E (58) have been found through hydrolysis of soyasaponins (59, 62, 
75) (Figure 4). Among them, soyasapogenol A (54) has two hydroxyl groups at C-21 and C-
22 position, which is considered as corresponding aglycones to bis-desmoside soyasaponin 
group A. Soyasapogenol B (55) has only one hydroxyl group at C-22 postion. It is considered 
to be aglycone of both monodesmoside soyasaponin groups B and DDMP. Soyasapogenol E 
(58) is regarded as the corresponding aglycone to soyasaponin group E. Soyasapogenols C 
(56) and D (57) are considered by some researchers not to be genuine aglycones of 
soyasaponins, but as the acid hydrolysis products of soyasapogenol B (55) (76). 
 
Fig. 4. The chemical structures of soyasapogenols A-E (hydrolysis products of soysaponins). 
2.2.2 Health effects of soyasaponins and soyasapogenols 
Plant saponins as a whole have been reported to have a wide range of biological activities, 
which were summarized with a long list in a recent review (77). Soyasaponins and 
soyasapogenols have been reported to display diverse health effects (78), including anti-
cancer, cardiovascular protective effects, anti-virus, hepatoprotective actions and 
antioxidant activities (24, 27, 79, 80). Their health effects largely depend on their chemical 
structures (81). Since this class of soy compounds are so poorly absorbed, their bioactivity 
maybe caused by indirect actions within the GI tract.  
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2.2.2.1 Anti-carcinogenic activities 
Epidemiological studies have linked soy consumption to lower incidences of various types 
of cancer (82). As a group of major phytochemicals in soy, soyasaponins may be partially 
responsible (27). The evidence for soyasaponins having anti-carcinogenic effects in animal 
models is limited. Nevertheless, soyasaponins and soyasapogenols have been shown to 
have the anti-carcinogenic effects in a number of carcinoma cell lines. Before summarizing 
the data, we must keep in mind that since soy saponins are poorly absorbed, in vitro studies 
of these compounds in cell lines may not be able to provide much meaningful indication 
regarding their in vivo bioactivities.  
Most studies related to the anti-carcinogenic activities of soyasaponins and soyasapogenols 
have been performed in human colon cancer, liver cancer or breast cancer cell lines (83-88). 
The proposed mechanisms of anticarcinogenic properties of soyasaponins and 
soyasapogenols include direct cytotoxicity, induction of apoptosis, anti-estrogenic activity, 
inhibition of tumor cell metastasis, anti-mutagenic activity effect, bile acid binding action 
and normalization of carcinogen-induced cell proliferation (Table 5) (89). From these studies 
done in different cancer cell lines, we’ve learned that there are at least three major factors 
that may affect the observed effects of soyasaponins and soyasapogenols. The first factor is 
the testing materials. Some researchers used crude extracts while others used purified 
saponins. It is possible that components of the crude extract interact synergistically, thus 
inducing effects not observed with pure saponins. Therefore, investigations with purified 
saponins are indispensable for matching a result to the molecular action of a specific 
saponin (90). The second factor is the type of cell lines. It is clearly shown that different 
cancer cell lines respond differently to soy saponins. For instance, soyasaponin I (35) had no 
effect on HT-29 colon cell growth (81), but it can decrease the migratory ability of B16F10 
melanoma cells (91). The third factor is the dose. In another study, soyasaponin III (37) 
showed significant growth suppression at the highest concentration tested (50 ppm), and no 
significant effects from concentrations 6 to 25 ppm.  
2.2.2.2 Cardiovascular protective effects 
Soyasaponins showed cardiovascular protective effects through several different 
mechanisms. 
The hypocholesterolemic effects of soy saponins have long been recognized (92-95). Two 
mechanisms by which saponins can affect cholesterol metabolism were suggested (96): 1) 
some saponins with particularly defined structural characteristics form insoluble complexes 
with cholesterol. When this complex-forming process occurs in the gut, it inhibits intestinal 
absorption of both endogenous and exogenous cholesterol. 2) Saponins can interfere with the 
entero-hepatic circulation of bile acids by forming mixed micelles. The re-absorption of bile 
acids from the terminal ileum is effectively blocked (92).  
In animal models, soyasaponins were found to significantly reduce serum total cholesterol 
(TC), low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG) concentrations, and to 
increase high-density lipoprotein-cholesterol (HDL-C) levels in rats (97). 24-
Methylenecycloartanol (59), in combination with soysterol greatly reduced plasma 
cholesterol and enhanced cholesterol excretion in rats (98). Hamsters fed group B 
soyasaponins had significantly lower plasma TC (by 20%), non-HDL-C (by 33%), TG (by 18%) 
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materials cell line dose observation mechanism ref 
Total soyasaponins Human 
HT-1080 
fibrosarc
oma cell 
Inhibit the metastasis of 
HT-1080 cells dose-
dependently (100-300 
g/ml) after 24 h. 
Inhibit the invasion 
of HT-1080 cells 
through a 
Matrigel-coated 
membrane. 
Suppress MMP-2 
and MMP-9 
productions and 
stimulate TIMP-2 
secretion. 
86 
Total soyasaponins Human 
HT-29 
colon 
cancer 
cell 
Decrease HT-29 cell 
growth in a dose 
dependent manner at 
concentrations of 150, 300, 
and 600 ppm after 72 h. 
Decrease HT-29 
cell growth. 
Suppress 
inflammatory 
reposponses. COX-
2 and PKC 
expressions were 
significantly down-
regulated. 
87 
Total soyasaponins Human 
HepG2 
liver 
hepatom
a cell 
Inhibit AFB1-DNA adduct 
formation in HepG2 liver 
hepatoma cells by 50.1 % at 
concentration of 30 g/ml 
after 48 h. 
Inhibit AFB1-DNA 
adduct formation 
in HepG2 liver 
cells.  
Induce membrane 
permeability 
change. 
85 
B-group 
soyasaponins 
Human 
SNB 19 
glioblast
oma cell 
Induce SNB 19 
glioblastoma cell apoptosis 
dose-depently (25-75 M) 
after 48 h. 
Induce apoptosis 
in SNB 19 
glioblastoma cells. 
Stimulate 
cytochrome-c 
release and activate 
caspase cascade. 
88 
B-group 
soyasaponins 
Human 
HCT-15 
colon 
cancer 
cell 
Suppress HCT-15 colon 
cancer cell proliferation 
dose-dependently at 
concentrations of 25-500 
ppm, and induce macro-
autophagy at concentration 
of 100 ppm after 24 h 
Suppress HCT-15 
colon cancer cell 
proliferation and 
induce 
macroautophagy. 
Delay S-phase cell 
cycle. 
83 
Soyasaponin I (35) Highly 
metastati
c B16F10 
melanom
a cell  
Decrease migratory ability 
of B16F10 melanoma cell 
dose-dependently (25-75 
M) after 12 h. 
Decrease the 
migratory ability of 
cells, enhance cell 
adhesion to 
extracellular 
matrix proteins. 
Inhibit the 
expression of -
2,3-linked sialic 
acids of B16F10 
melanoma cell. 
91 
Soyasaponin I (35) Human 
MCF-7 
breast 
cancer 
cell. 
Significantly enhance 
MCF-7 cells to adhere the 
extracellular matrix at 50 
M after 24 h. 
Enhance the 
adhesion of MCF-7 
cells to the 
extracellular 
matrix proteins. 
Alter MCF-7 breast 
cancer cell surface 
2,3-sialylation 
pathway. 
84 
Soyasaponin III (37) 
 
Soyasapogenol B 
monoglucuronide 
 
Soyasapogenol A (54) 
 
Soyasapogenol B (55)
Human 
HT-29 
colon 
cancer 
cell 
37 and soyasapogenol B 
monoglucuronide show 
HT-29 colon cancer cell 
growth suppression at 50 
ppm after 72 h. 
 
54 and 55 show a dose-
dependent growth 
suppression from 6- 50 
ppm after 72 h. 
They all suppress 
the growth of HT-
29 colon cancer cell
The cell growth 
suppression of 
soyasaponins and 
soyasapogenols 
increased with 
increased 
lipophilicity. 
81 
Table 5. The anti-carcinogenic activities of soyasaponins and soyasapogenols 
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and a lower ratio of total to HDL cholesterol (by 13%) in hamsters fed group B 
soyasaponins, compared to those fed casein. Possible mechanisms involved greater 
excretion of fecal bile acids and neutral sterols (99). 
The anti-thrombogenic action of soyasaponins was evaluated in a model of disseminated 
intravascular coagulation (DIC) induced by infusion of endotoxin or thrombin in rats. Total 
soyasaponins prevented the decrease of blood platelets and fibrinogen, and the increase of 
fibrin degradation products during DIC induced by infusion of endotoxin or thrombin in 
rats. In vitro experiments, total soyasaponins, soyasaponins I (35), II (36), A1 (27), and A2 (28) 
inhibited the conversion of fibrinogen to fibrin (100).  
Total soyasaponins decreased elevated blood sugar and LPO levels, and reversed the 
decreased levels of SOD in streptozocin-induced diabetic rats (101). In an -glucosidase 
inhibitory assay, groups B, E and DDMP soyasaponins were shown to have potent 
inhibitory activities with IC50 values of 10-40 mol/L (102). 
2.2.2.3 Anti-viral activities 
Soyasapogenols A (54), B (55), E (58), and soyasaponin I (35), a major constituent of group B 
saponins, completely inhibited HIV-induced cytopathic effects 6 days after infection at 
concentration greater than 0.25 mg/mL, but had no direct effect on HIV reverse 
transcriptase activity. Soyasaponin I (35) also inhibited HIV-induced cell fusion in the 
MOLT-4 cell system (103).  
Total soyasaponins showed significant inhibitory effect on the replication of HSV-1 and 
CoxB3. A soyasaponin cream was used in the treatment of patients suffering from herpes 
labialis. The treatment was found to be highly effective with a cure rate of 88.8% for the 
disease (104). Soyasaponin II (36) is more potent than soyasaponin I (35) as shown by a 
reduction of simplex virus type 1 (HSV-1) production. Soyasaponin II (36) was also found to 
inhibit the replication of human cytomegalovirus and influenza virus. This action was not 
due to inhibition of virus penetration and protein synthesis, but may involve a virucidal 
effect (105). In a structure–activity relationship study, the activity of soyasapogenol A (54) 
was less than 1/20 of that of soyasapogenol B (55), and the hydroxylation at C-21 seemed to 
reduce anti-HSV-1 activity (106). 
2.2.2.4 Hepatoprotective actions 
The group B soyasaponins I (35), II (36), III (37), and IV (38) all exhibit hepato-protective 
actions towards immunologically induced liver injury in primary cultured rat hepatocytes. 
The action of soyasaponin II (36) is almost comparable with that of soyasaponin I (35), 
whereas soyasaponins III (37) and IV (38) are more effective than soyasaponins I (35) and II 
(36). This suggests that the disaccharide group shows greater action than the trisaccharide 
group. Furthermore, the soyasaponins having a hexosyl unit shows a slightly greater action 
than that of the pentosyl unit in each disaccharide group or trisaccharide group. Structure-
activity relationships suggest that the sugar moiety linked at C-3 may play an important role 
in hepato-protective actions of soyasaponins (107). 
Also in in vivo experiments, total soyasaponins inhibit the elevation of liver transaminases 
when administered orally to rats with peroxidized corn oil. The liver injury caused by 
peroxidized salad oil is inhibited by the addition of soyasaponin A1 (27) during peroxidation 
(108). 
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2.2.2.5 Antioxidant activities 
One mg of DDMP saponin/mL scavenges superoxide at a degree equivalent to 17.1 units of 
superoxide dismutase/mL by the ESR spin trapping method. The scavenging superoxide 
activity of DDMP soyasaponins is caused by the DDMP moiety attached to the triterpene 
aglycon since soyasaponin I (35), which is derived from soyasaponin βg (50). Lack of this 
group didn’t show the scavenging activity (109). 
2.3 Triterpenes and sterols 
2.3.1 Chemical characteristics of triterpenes and sterols 
Triterpenes and sterols are found in soybean oil unsaponifiable matter. They are both 
present in minor quantities.  
Three triterpenes have been identified in soy. They are 24-methylenecycloartenol (59) (98), 
cycloartenol (60) (98) and bacchara-12,21-dien-3-ol (61) (Figure 5) (110), respectively. 
Compounds 59 and 60 belong to the type of lanostane triterpene. In addition to having the 
basic structural characters of lanostane, they bear an extra tri-atomic ring in their structures 
that are formed by cyclization between methyl at C-18 and methine at C-9. Lanostane 
triterpenes in soy were believed to be the original materials for the biosynthesis of soy 
sterols. Bacchara-12,21-dien-3-ol (61) is a natural occurring of baccharane-type triterpene 
which has all six-membered tetracyclic skeleton, and its side chain is at position C-17. This 
type of triterpene is extremely rare in nature and no more than 20 compounds of this type 
have been separated and identified. 
Cholesterol and thirteen so-called plant sterols or phytosterols were found in soybean seed 
or the shoots (111) (Figure 6). Unlike animals, plant membranes generally contain little or no 
cholesterol and instead contain several types of phytosterols. Phytosterols are also steroid 
alcohols, whose chemical structures are similar to that of cholesterol, but with the presence 
of one or two carbon, saturated or unsaturated, substituents in side chains at C-24 differing 
from that of cholesterol (62) (Figure 6) (26, 111). The most abundant phytosterols are 
sitosterol, compesterol and stigmasterol (112). Phytosterols identified from soy so far 
include cholesta-5,24-dien-3-ol (63), -sitosterol (64) (113), stigmasterin (65) (24), sitostanol 
(66)(114), citrostadienol (67) (113), isofucosterol (68) (111), campesterol (69) (115), 24-
epicampesterol (70) (115), 7-dehydrocampesterol (71) (115), campestanol (72) (111), 
obtusifoliol (73) (111), 24-methylenelophenol (74) (111), and 14-methyl-5-ergost-8-en-3-ol 
(75) (111). The most abundant soy phytoserol is -sitosterol (64), followed by campesterol 
(69) (112). These sterols can be divided into four groups based on their backbones, 
cholesterol (62), cholesta (63), stigmasta (64-68) and ergosta (69-75) (Figure 6). Compounds 
62 and 63 have the same backbone except for the type of bond between C-24 and C-25. The 
former is single bond while the latter is double bond (Figure 6). Stigmasta and ergosta also 
share similar structures with the only difference for stigmasta being that it has one more 
methyl group at C-28 (Figure 6). However, nutritionists prefer to divide the phytosterols 
into two categories of “5-sterols”, indicating a double bond at position C-5, and “stanol”, 
indicating 5-reduction of that double bond (114). According to this principle, compounds 
62-65 and 68-71 are 5-sterols; 66-67 and 72-75 are stanols (Figure 6). 
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Fig. 5. The chemical structures of triterpenes in soy. 
2.3.2 Health effects of phytosterols 
Phytosterols (not restricted to soy-based sources) that have long been known to reduce 
intestinal cholesterol absorption, lead to decreased blood LDL-cholesterol levels and lower 
cardiovascular disease risk. However, other biological activities for phytosterols have also 
been reported, including anti-cancer and immune modulatory effects.  
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Fig. 6. The chemical structures of sterols in soy. 
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2.3.2.1 Phytosterols and cholesterol absorption 
In the 1950’s, phytosterols from soybeans were found to lower serum cholesterol level (116). 
Since then, the cholesterol-lowering effects of phytosterols have been extensively 
demonstrated in both humans and animals (117-120). A meta-analysis of 41 clinical trials 
showed that intake of 2 g/d of stanols or sterols reduced low-density lipoprotein (LDL) by 
10%, with little additional reduction at higher doses (121). The U.S. National Cholesterol 
Education Program has recommended adding 2.0 g/day of phytosterols to the diet of adults 
to reduce LDL cholesterol and coronary heart disease risk (122).  
Because phytosterols are not systemically absorbed, they are thought to act primarily in the 
intestinal lumen. As cholesterol analogs phytosterols compete for cholesterol in absorptive 
micelles resulting in reduced solubility of cholesterol (118). However, recent evidence 
suggests that the mechanism of action of phytosterols may be more complicated than 
originally thought (119, 123). As summarized in a recent review (123), since 
phytosterols/phytostanols do not need to be present in the intestinal lumen simultaneously 
with cholesterol to inhibit its absorption (120), other studies have suggested that 
phytosterols/phytostanols may exert an unknown molecular action inside enterocytes and 
hepatocytes. In line with this, injected phytosterols/phytostanols reduced plasma 
cholesterol levels in hamsters (124). To gain insight into the phytosterol/phytostanol affects 
on circulating cholesterol concentration via mechanisms independent of the luminal 
incorporation of cholesterol into mixed micelles, the effects of these plant compounds on 
intestinal LXR-mediated targets involved in sterol absorption have been evaluated. 
Conclusive studies using ABCA1 and ABCG5/G8-deficient mice demonstrated that the 
phytosterol-mediated inhibition of intestinal cholesterol absorption is independent of these 
ATP-binding cassette (ABC) transporters. Other reports have raised questions as to whether 
phytosterols/phytostanols regulate cholesterol metabolism in intestinal and hepatic cells 
through independent-LXR pathways. A number of studies have proposed a 
phytosterol/phytostanol action on cholesterol esterification and lipoprotein assembly 
(ACAT, apoB), cholesterol internalisation (NPC1L1, ANXA2), cholesterol synthesis (HMG-
CoA reductase, C-24-reductase) and removal of apoB100-containing lipoproteins (LDLr). 
However, the impact of phytosterol/phytostanol intake on these physiological processes in 
vivo remains unclear (123). 
In one study specifically using soybean-derived phytosterols (125), it was found that 
consumption of phytosterol-supplemented ground beef lowered plasma TC and LDL-
cholesterol concentrations and TC:HDL cholesterol from baseline by 9.3%, 14.6%, and 9.1%, 
respectively.  
2.3.2.2 Anti-cancer effects of phytosterols 
In addition to their cholesterol-lowering actions, mounting evidence suggests that 
phytosterols possess anti-cancer effects against a number of different types of cancers (126-
132). Phytosterols seem to act through multiple mechanisms of action, including inhibition 
of carcinogen production, cancer-cell growth, angiogenesis, invasion and metastasis, and 
through the promotion of apoptosis of cancerous cells. Phytosterol consumption may also 
increase the activity of antioxidant enzymes and thereby reduce oxidative stress. In addition 
to altering cell-membrane structure and function, phytosterols probably promote apoptosis 
by lowering blood cholesterol levels (127). 
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2.3.2.3. Physterols and immune function 
Several reports in the literature suggest that phytosterols may have some immunological 
activity as highlighted in animal models of inflammation or even in in vitro and in vivo 
models of cancer (colorectal and breast cancer). Their direct immune modulatory activity on 
human lymphocytes has been proven, and the mechanism of action in cancer cells has been 
elucidated (133, 134). 
2.4 Lignans 
2.4.1 Chemical characteristics of lignans 
In addition to isoflavones, lignans are considered another main group of phytoestrogens in 
soy, based on their chemical structures. Lignans are defined as dimeric phenylpropanoid 
(C6-C3) compounds, mostly linked at 8-8′ (Figure 7) (135, 136). They are seven lignans 
identified from soy, namely, anhydrosecoisolariciresinol (76), isolariciresinol (77), 
secoisolariciresinol (78), matairesinol (79), lariciresinol (80), pinoresinol (81) and 
syringaresinol (82) (Figure 7) (28, 137). 
2.4.2 Health effects of lignans 
2.4.2.1 Antioxidant activity  
Pinoresinol (81) has been reported frequently as an antioxidant, using thiocyanate 
antioxidant, Cu2+-induced low density lipoprotein oxidation, lipid peroxidation in rat 
liver, DPPH radical, and peroxy radical assays (138). Syringaresinol (82) has also been 
demonstrated as antioxidative in Cu2+-induced low density lipoprotein oxidation and 
DPPH radical assays (138). Lariciresinol (80) has a high radical scavenging capacity 
compared to the well-known antioxidant Trolox. The trapping capacity (mmoles peroxyl 
radicals scavenged per gram of compound) of lariciresinol (80) (7.3 mmol/g) is higher 
than that of trolox (6.8 mmol/g) (139). Secoisolariciresinol (78) showed strong antioxidant 
activity against DPPH with an IC50 of 0.017±0.001 mM. It is about two times stronger than 
the standard antioxidant, 2,6-di-(tert-butyl)-4-methylphenol (BHT), IC50 0.0310.001 mM 
(140). Isolariciresinol (77) showed 86.2 % inhibition of lipid peroxidation (LPO) at 25 
g/ml (141). 
2.4.2.2 Anticancer activity 
Estrogenic enterolignans, END or ENL are the major metabolites of lignans in the 
mammalian gut. Because estrogens were linked to some cancers, especially breast cancer, 
enterolignans could affect some cancer risk. To our knowledge, the estrogenic or anti-
estrogenic effects of enterolignans in humans are not very clear (142). For example, while 
weak estrogenic activity of ENL was demonstrated the anti-estrogenic activity of ENL 
was disclosed through depression of estrogen-stimulated rat uterine RNA synthesis 
(143). 
The lignan ENL was found to have a bi-phasic effect on DNA synthesis in human breast 
cancer MCF-7 cells, showing induction at 10-50 M and inhibition at higher concentrations, 
with an IC50 of 82.0 M (144). END and ENL are weak and moderate inhibitors of aromatase 
enzyme activity in a pre-adipose cell culture system (143). In human colon tumor cell 
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Fig. 7. The chemical structures of lignans in soy. 
lines (LS174T, Caco-2, HCT-15, T-84), the same concentration of END and ENL (100 µM) 
significantly reduce the proliferation of all cell lines, though ENL was more than twice as 
effective as END (145). 
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2.5 Phytate 
2.5.1 Chemical characteristics of phytate 
Phytate (83), the salt of phytic acid (myo-inositol-(1,2,3,4,5,6)hexakisphophate, IP-6, InsP-6) 
(Figure 8), is a naturally occurring polyphosphorylated carbohydrate. It is widely 
distributed in the plant kingdom. Phytate serves as a storage form of phosphorous and 
minerals and contains ~75% of total phosphorous of the kernels (25). It is the major source of 
phosphorus in soy (79). Phytate is considered as a strong chelator of important minerals 
such as calcium, magnesium, iron, and zinc, and can contribute to mineral deficiencies in 
people. However, recent studies demonstrate that this “antinutrient” effect of IP6 is only 
manifested when large quantities of IP6 are consumed in combination with an 
oligoelements-poor diet (146). 
 
Fig. 8. The chemical structures of phytic acid in soy.  
2.5.2 Health effects of phytic acid 
2.5.2.1 Anti-cancer activities 
Phytic acid (83) plays an important role in signal transduction, cell proliferation and 
differentiation (147). Recently phytic acid (83) has received much attention for its role in 
cancer prevention and control of experimental tumor growth, progression, and metastasis 
(148). A great majority of the studies were done in animals and showed that phytic acid had 
anti-neoplastic properties in breast, colon, liver, leukemia, prostate, sarcomas, and skin 
cancer (149, 150). The results and proposed mechanism of anti-carcinogenic activities of IP6 
in various cell lines are summarized in Table 6 (151-154).  
In animal studies, phytic acid can increase blood NK cell activity in DMH-induced colon 
tumors in rats, suppress rhabdomyosarcoma cell growth in a xeno-grafted nude mouse 
model (155), inhibit tumor growth and metastasis in rats (156), prolong survival of tumor-
bearing mice, and reduce the numbers of pulmonary metastases (157). Phytic acid can also 
inhibit DMBA-induced mouse skin tumor development and this inhibitory effect is likely, 
by modulating proliferation, differentiation, or apoptosis (158).  
2.5.2.2 Other health effects 
For a long time IP6 has been recognized as a natural antioxidant. In addition, IP6 possesses 
other significant benefits for human health, such as the ability to enhance the immune  
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cell line dose observation mechanism ref 
Human Caco-2 
colon cancer 
cell 
Decrease the expression of TNF- 
and TNFII in a dose dependent 
manner (1, 2.5 and 5 mM) after 12 
h. 
Decrease the 
expression of TNF- 
and TNFII in Caco-2 
cells. 
Regulate cytokine 
production including 
TNF-, to modulate 
immune response and 
cell death activation. 
147 
Human HT-29 
colon cancer 
cell 
Inhibit proliferation of HT-29 cells 
at 8 mmol/L and 13 mmol/L after 
12 h. 
Inhibit proliferation 
of HT-29 cells  
Affect special cell cycle 
regulators, reduce over-
expression of mutant 
P53, and prevent 
PCNA-dependent 
cellular proliferation. 
154 
Human MCF-
7/Adr MDA-
MB 231 and 
MCF-7 breast 
cancer cells 
MCF-7/Adr – IC50 1.26 mM 
MDA-MB 231– IC50 1.32 mM 
MCF-7– IC50 4.18 mM after 96 h. 
Inhibit the growth of 
three breast cancer 
cells 
Change cell cycle 
distribution 
153 
Human 
HepG2 liver 
hepatoma cell 
Inhibit the growth of HepG2 liver 
hepatoma cell in a dose-dependent 
fashion (0.25-5 mM) after 6 days. 
Inhibit the growth of 
HepG2 liver 
hepatoma cell 
Modulate cell signal 
transduction pathways 
155 
Human 
LNCaP 
prostate cancer 
cell 
Inhibit the growth of LNCaP 
prostate cancer cell dose 
dependently (0.5-4 mM) after 24 h.
Inhibit the growth of 
LNCaP prostate 
cancer cell 
Inhibit Akt activation, 
cause CDKI 
accumulation and 
induce LNCaP cell 
cycle arrest. 
151 
Human DU145 
prostate cancer 
cell 
Inhibit the growth of DU145 
prostate cancer cell dose 
dependently (0.25-2 mM) after 24 h.
Inhibit the growth of 
DU145 prostate 
cancer cell 
Induce G1 arrest in 
DU145 cell cycle 
progression. 
152 
Table 6. The anti-carcinogenic activities of IP 
system, prevent pathological calcification and kidney stone formation, lower elevated serum 
cholesterol, and to reduce pathological platelet activity (148). IP6 inhibited the replication of 
HIV-1 in a T cell line and in a freshly isolated strain in peripheral blood mononuclear cells, 
possibly acting on HIV-1 early replicative stage (149) 
 
Fig. 9. The chemical structures of cinnamic acid ester glycosides in soy. 
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2.6 Cinnamic acid ester glycosides 
2.6.1 Chemical characteristics of cinnamic acid ester glycosides 
Two cinnamic acid ester glycosides were isolated by Hosny et al from soybean molasses, 
which is a by-product of aqueous alcohol soy protein concentrate production (70). They were 
identified as 1-O-(E)-feruloy[-L-arabinofuranosyl-(13)][-D-glucopyranosyl(16)]-D-
glucopyranose (84) and 1-O-(E)-3,4,5-trimethoxycinnamoyl[-L-arabinofuranosyl(13)] 
[glucopyranosyl(16)]-D-glucopyranose (85) (Figure 9).  
3. Constituents formed during processing 
Food processing may dramatically change the compositions and relative contents of the 
constituents in soy products and artificial compounds may also occur (159). The processing 
of foods can improve nutrition, quality, and safety; though processing could also lead to the 
formation of anti-nutritional and toxic compounds. These multi-faceted consequences of 
food processing result from molecular interactions among nutrients and with other food 
ingredients, both natural and added (160).  
Some components isolated from soy products such as soy sauce and fermented products do 
not occur naturally in the soybean. And the types of these compounds vary among different 
soy products based upon processing methods. These compounds may be formed by 1) 
soybean processing or fermentation; 2) compounds from other ingredients of soy products; 
3) compounds from reactions of components in soybean and/or other ingredients during 
processing. Even though these compounds are not found naturally in soybean, they do exist 
widely in various soy products and may contribute to important beneficial or detrimental 
biological effects associated with soy consumption. Unfortunately, the key role of these 
compounds is largely ignored.  
In Japan, soybeans molasses and soy fermented with Bacillus subtilis (natto) are very popular 
daily foodstuffs (161). Six isoflavones which differ from that isolated from soy were generated 
by this process. They are glycitein 7-O--D-(2,4,6-O-triacetyl)glucopyranoside (86), 8-(-
hydroxy-,-dimethylpropyl)genistin (87), 5-hydroxy-8-(-hyroxy-,-dimethylpropyl)-3,4-
dimethoxyisoflavone-7-O--D-glucopyranoside (88), 6-O-succinyldaidzin (89), 6-O-
succinylgenistin (90), and 6-O-succinylglycitin (91) (161, 162) (Figure 10). 
Another group of well-known compounds formed during food processing in soy is The 
Maillard reaction products (163, 164). The Maillard reaction is the heat-induced reaction of 
amino groups of amino acids, peptides, and proteins with carbonyl groups of reducing 
sugars such as glucose, that results in the concurrent formation of so-called Maillard 
browning products and acrylamide (165). In the past, extensive work has been done on 
Maillard reaction products in food products including several excellent reviews (160, 164-
167). Five Maillard reaction products, fructose-lysine (92), fructose-alanine (93), fructose-
valine (94), fructose-leucine (95) and fructose-isoleucine (96) (Figure 11) were isolated from 
soy sauce and miso (168, 169).  
Other groups of compounds may also be found in different soy products. Guided by platelet 
aggregation analysis, two anti-platelet alkaloids, 1-methyl-1,2,3,4-tetrahydro--carboline (97) 
and 1-methyl--carboline (98), were obtained from soy sauce. These two compounds 
inhibited the maximal aggregation response induced by epinephrine, platelet-activating 
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Fig. 10. The chemical structures of new isoflavones generated during food processing in soy 
products. 
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Fig. 11. The chemical structures of other components generated during food processing in 
soy products. 
factor, collagen, adenosine 5-diphosphate, and thrombin, respectively (170). Compound 97 
had much greater inhibitory effect than that of 98 on platelet aggregation. Three other 
alkaloids, asperparalines A (99), B (100) and C (101) were found from okara (the insoluble 
residue of whole soybean) fermented with Aspergillus japonicus JV-23 (Figure 11) (171). Since 
soybean does not contain alkaloids, these compounds were likely brought into the soy 
products from other sources. 
A series of aromatic compounds were isolated from soy sauce and miso (a traditional 
Japanese seasoning produced by fermented soybeans) (172-174). Their structures were 
identified as 4-hydroxy-2-ethyl-5-methyl-3(2H)-furanone (HEMF; 102), 4-hydroxy-5-ethyl-2-
methyl-3(2H)-furanone (103) ), 2,5-dimethyl-4-hydroxy-3(2H)-furanone (DMHF; 104) and 3-
hydroxy-2-methyl-4H-pyran-4-one (maltol;105) (Figure 11). They are considered to form the 
base of the sweet aroma of miso. All of these compounds were most likely generated during 
soy processing and/or fermentation.  
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Processing may also significantly elevate or reduce certain naturally occurring soybean 
components. For instance, a remarkable increase in folate content was found after 
fermentation, 5.2-fold and 1.7-fold higher than that of the boiled soybeans and soybean 
seeds, respectively (175). Thus, we must be aware that the composition of soybean products 
may differ substantially from the native soybean.  
4. Conclusion 
The soy bean has been used as a human food source of high quality protein and other 
nutrients for hundreds of years and is currently a major source of protein in commercial 
food products for the beef, pork and chicken industry. This chapter summarizes our current 
knowledge about chemical structures and health effects of the major phytochemicals in soy. 
Clearly, the observed health effects from soy or soy-based foods (other than those attributed 
to nutrients like protein) are not solely from the actions of certain individual or types of 
compounds, but rather are due to the mixed effects of different compounds. Additive, 
synergistic, and/or antagonistic effects of different soy components combine to provide a 
final effect of soy foods and these effects may also be altered by phytochemicals from other 
non-soy foods in the meal. In order to fully understand the mechanism of health effects of 
soy, it is important to identify the genuine bioactive compounds in soy.  
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